Vericel (VCEL) Liabilities and Shareholders Equity (2010 - 2026)

Vericel (VCEL) reported Liabilities and Shareholders Equity of $485.6 million for Q1 2026, up 14.38% on a YoY basis from $424.6 million in Q1 2025, and little changed sequentially from $488.0 million in Q4 2025.

Vericel (VCEL) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends

Vericel (VCEL) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $485.6 million in Q1 2026.

  • For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 14.38% year-over-year to $485.6 million; the trailing twelve-month figure through Mar 2026 stood at $1.9 billion (up 14.65% YoY), and the FY2025 full-year result was $488.0 million, up 12.77% from the prior year.
  • Liabilities and Shareholders Equity was little changed at $485.6 million in Q1 2026, from $488.0 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $488.0 million in Q4 2025 to a low of $240.3 million in Q1 2022.
  • A 5-year average of $358.7 million and a median of $356.7 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
  • Across the five-year window, Liabilities and Shareholders Equity climbed 10.3% in 2022 and jumped 34.54% in 2024, its largest moves.
  • Tracing VCEL's Liabilities and Shareholders Equity over 5 years: stood at $273.0 million in 2022, then grew by 29.54% to $353.7 million in 2023, then increased by 22.36% to $432.7 million in 2024, then rose by 12.77% to $488.0 million in 2025, then fell by 0.48% to $485.6 million in 2026.
  • Business Quant data shows VCEL's Liabilities and Shareholders Equity at $485.6 million in Q1 2026, $488.0 million in Q4 2025, and $453.3 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 311.58 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 78.88 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 8.55 Bn
4 NuCana 279.75 Bn 279.75 Bn - 39.68 Mn
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 26.48 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 40.87 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - 811.27 Mn
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 10.03 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn - 2.25 Bn
10 Vericel 2.30 Bn 2.15 Bn 49.27 Mn 485.63 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 485.63 Mn
Dec 31, 2025 487.97 Mn
Sep 30, 2025 453.27 Mn
Jun 30, 2025 435.61 Mn
Mar 31, 2025 424.59 Mn
Dec 31, 2024 432.72 Mn
Sep 30, 2024 390.41 Mn
Jun 30, 2024 376.84 Mn
Mar 31, 2024 356.66 Mn
Dec 31, 2023 353.66 Mn
Sep 30, 2023 318.13 Mn
Jun 30, 2023 310.71 Mn
Mar 31, 2023 265.10 Mn
Dec 31, 2022 273.00 Mn
Sep 30, 2022 248.02 Mn
Jun 30, 2022 244.82 Mn
Mar 31, 2022 240.29 Mn
Dec 31, 2021 243.71 Mn
Sep 30, 2021 224.14 Mn
Jun 30, 2021 221.95 Mn